Literature DB >> 3149968

Cromolyn sodium does not prevent hypoxia-induced pulmonary hypertension in newborn and young lambs.

E G Frantz1, M D Schreiber, S J Soifer.   

Abstract

Hypoxia-induced pulmonary hypertension may be mediated by leukotrienes. Pulmonary mast cells produce leukotrienes, histamine and prostaglandin D2, and degranulate in response to hypoxia. Cromolyn sodium, a mast cell membrane stabilizing agent, may prevent hypoxia-induced mast cell degranulation. To investigate the role of mast cell products in hypoxia-induced pulmonary hypertension, we studied the haemodynamic responses to alveolar hypoxia before and during an intravenous infusion of 3-5 mg/min per kg of cromolyn sodium in 6 chronically instrumented, spontaneously breathing lambs. Since there are age-dependent differences in the response of the pulmonary circulation to some mast cell products, we studied the effects of cromolyn sodium on hypoxia-induced pulmonary hypertension in newborn (4-7 days) and young lambs (15-18 days). During alveolar hypoxia, mean pulmonary arterial pressure increased by 68% (P less than 0.05) and 59% (P less than 0.05) in the newborn and young lambs, respectively. With alveolar hypoxia during cromolyn sodium infusion, mean pulmonary arterial pressure increased by 71% (P less than 0.05) and 42% (P less than 0.05) in the newborn and young lambs, respectively. Cromolyn sodium did blunt the hypoxia-induced release of histamine into the circulation. Because hypoxia-induced pulmonary hypertension was not inhibited by cromolyn sodium in either age group, mast cell products are not important mediators of hypoxia-induced pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3149968

Source DB:  PubMed          Journal:  J Dev Physiol        ISSN: 0141-9846


  1 in total

1.  Acute and chronic hypoxia as well as 7-day recovery from chronic hypoxia affects the distribution of pulmonary mast cells and their MMP-13 expression in rats.

Authors:  Ludek Vajner; Richard Vytásek; Vera Lachmanová; Jirí Uhlík; Václava Konrádová; Jana Novotná; Václav Hampl; Jan Herget
Journal:  Int J Exp Pathol       Date:  2006-10       Impact factor: 1.925

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.